Nasdaq:TIVC
Tivic Health Systems, Inc.
A niche medical device manufacturer focused on minimally invasive urologic surgical tools facing severe revenue contraction and persistent operating losses.
Key Metrics
Investment Thesis
Bull Case
The stock may offer speculative value for investors betting on a potential strategic acquisition by a larger medical technology firm seeking to diversify their surgical portfolio. If management can successfully pivot product offerings or enter new therapeutic areas, the current depressed valuation could provide substantial upside upon stabilization. The company's total assets of $2.8M and minimal long-term liabilities present a low-risk balance sheet should a turnaround strategy succeed.
Bear Case
Investors should avoid this stock due to four consecutive years of net losses totaling over $34M without any path to positive free cash flow visible in the data. The steep revenue decline from $1.8M to under $1M indicates a failing business model that cannot generate organic growth or market share gains. Persistent reliance on equity financing to cover operating deficits suggests the company will likely dilute shareholders further before ever becoming profitable.
About Tivic Health Systems, Inc.
Tivic Health Systems designs and manufactures medical devices for minimally invasive urologic procedures, primarily serving the US healthcare market with a focus on advanced surgical solutions. The company leverages its proprietary technology to provide specialized tools that enhance precision during complex surgical interventions while maintaining a lean operational footprint. With revenue declining from $1.8M in 2022 to $780k in the latest fiscal year, the firm faces significant headwinds in sustaining commercial momentum.
Analysis
Management Discussion
Management has struggled to halt revenue decline, with total revenue dropping by 35% year-over-year as the company burns through cash reserves at a rate of $5.7M annually. Despite efforts to reduce working capital requirements via inventory and receivable management, operating expenses remain high relative to shrinking sales volumes. The company continues to rely on financing activities to cover operational shortfalls, masking underlying profitability issues with significant share issuances.
Industry Overview
The medical device industry is highly competitive with high barriers to entry driven by regulatory approval processes and extensive clinical trial requirements. Companies in urology focus often face pressure from established giants like Johnson & Johnson or Medtronic who dominate market share through broad portfolios. Success in this niche typically requires continuous innovation to stay ahead of evolving surgical techniques and reimbursement policies.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $1.8M | $1.2M | $780.0K |
| Cost of Revenue | $1.5M | $889.0K | $778.0K |
| Gross Profit | $299.0K | $287.0K | $2.0K |
| Operating Expenses | $10.4M | $8.5M | $5.7M |
| Operating Income | $-10.1M | $-8.2M | $-5.7M |
| R&D | $1.7M | $1.7M | $1.3M |
| G&A | $5.9M | $4.8M | $3.2M |
| Marketing | $2.8M | $2.1M | $1.2M |
| Stock-Based Comp | $398.0K | $271.0K | $229.0K |
| D&A | — | $8.0K | $3.0K |
| Depreciation | $10.0K | $8.0K | $3.0K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $1.0K | $0 |
| Pre-Tax Income | $-10.1M | $-8.2M | $-5.7M |
| Income Tax | $-2.0K | $0 | $-6.0K |
| Continuing Ops | $-10.1M | $-8.2M | $-5.7M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-10.1M | $-8.2M | $-5.7M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-10.1M | $-8.2M | $-5.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $5.3M | $4.7M | $2.6M |
| Cash & Equivalents | $3.5M | $3.4M | $2.0M |
| Accounts Receivable | $88.0K | $174.0K | $69.0K |
| Inventory | $863.0K | $756.0K | $319.0K |
| Prepaid Expenses | $235.0K | $327.0K | $249.0K |
| Other Current Assets | $584.0K | $0 | $0 |
| Long-Term Assets | $569.0K | $505.0K | $168.0K |
| PP&E (Net) | $12.0K | $122.0K | $119.0K |
| Operating Leases | $523.0K | $349.0K | — |
| Other LT Assets | $34.0K | $34.0K | $49.0K |
| Total Assets | $5.9M | $5.2M | $2.8M |
| Current Liabilities | $1.9M | $1.4M | $272.0K |
| Accounts Payable | $1.3M | $713.0K | $125.0K |
| Current Leases | $163.0K | $193.0K | — |
| Other Current Liab | $373.0K | $495.0K | $147.0K |
| Long-Term Liabilities | $367.0K | $176.0K | $0 |
| LT Operating Leases | $367.0K | $176.0K | — |
| Other LT Liab | $0 | $0 | — |
| Total Liabilities | $2.2M | $1.6M | $272.0K |
| Shareholders' Equity | $3.6M | $3.6M | $2.5M |
| Paid-In Capital | $33.3M | $41.5M | $46.1M |
| Retained Earnings | $-29.6M | $-37.9M | $-43.5M |
| Total L&E | $5.9M | $5.2M | $2.8M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-10.1M | $-8.2M | $-5.7M |
| Non-Cash Adjustments | $858.0K | $317.0K | $1.5M |
| Working Capital Changes | $319.0K | $-584.0K | $-1.6M |
| Cash from Operations | $-8.9M | $-8.5M | $-5.7M |
| Capital Expenditures | $11.0K | $118.0K | — |
| Cash from Investing | $-11.0K | $-118.0K | $0 |
| Cash from Financing | $-528.0K | $8.5M | $4.3M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-9.5M | $-122.0K | $-1.4M |
| Beginning Cash | $13.0M | $3.5M | $3.4M |
| Ending Cash | $3.5M | $3.4M | $2.0M |
Frequently Asked Questions
How does Tivic Health Systems, Inc. make money?
Primary revenue stream derived from sales of proprietary minimally invasive surgical systems for urology; Secondary income from specialized consumables and accessories bundled with device platforms; Minor revenue potentially generated through strategic partnerships or licensing agreements in the orthopedic sector.
What are the main risks for TIVC?
Sustained negative operating cash flow of $5.7M indicating an inability to fund growth or operations without external capital; Declining revenue trend over the last three years suggesting market saturation or loss of competitive positioning; Significant accumulated retained earnings deficit of $43.5M reflecting historical financial distress; Heavy reliance on equity issuance ($4.4M) to finance operations raises concerns about shareholder dilution.
What is TIVC's competitive advantage?
Proprietary intellectual property protecting core surgical device designs against generic competition; Specialized engineering team capable of rapid iteration on complex minimally invasive mechanisms; Established relationships with select hospital systems and urology groups for early product adoption.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.